Official website (https://www.biogen.com/)
Biogen
Also known as Biogen Inc., BIIB, Biogen Idec
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0
Key facts
- Company.name
- Biogen Inc.
- Company.logo
- Biogen.svg
- Company.logo_size
- 250px
- Company.image
- Biogen.jpg
- Company.image_size
- 240px
- Company.image_caption
- Headquarters in Cambridge, Massachusetts
- Company.former_name
- Biogen Idec Inc. (2003–2015)
- Company.type
- Public
- Company.industry
- Biotechnology
- Company.revenue
- (2025)
- Company.operating_income
- US$1.86billion (2025)
- Company.net_income
- US$1.29billion (2025)
- Company.assets
~20 min read
Article
14 sectionsContents
- History
- 2000s
- 2010s
- 2020s
- Conference super spreadaer event during COVID-19 pandemic
- Aducanumab
- Acquisition history
- Finances
- Products
- Pipeline
- Lawsuits
- See also
- References
- External links
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.
On the map
3 mapped locations
Connections
Categories
1991 initial public offerings2003 establishments in MassachusettsBiotechnology companies established in 1978Biotechnology companies of the United StatesCompanies based in Cambridge, MassachusettsCompanies listed on the NasdaqCoordinates not on WikidataHealth care companies based in MassachusettsLife science companies based in MassachusettsLife sciences industryNational Medal of Technology recipients